Recruiting

Expression of Progesterone Membrane Receptors in Placentas From Pregnancies Complicated by Intrauterine Growth Restriction: A Prospective Observational Case-Control Study

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected from today forward - Prospective
Who is being recruted

Urogenital Diseases+6

+ Female Urogenital Diseases and Pregnancy Complications

+ Fetal Diseases

From 18 to 45 Years
+2 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Case-Control

Comparing exposures between individuals with and without disease in order to identify potential risk factors.
Observational
Study Start: November 2025
See protocol details

Summary

Principal SponsorSamsun University
Study ContactCanan SOYER ÇALIŞKAN, MD, Associate ProfessorMore contacts
Last updated: July 14, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: November 1, 2025

Actual date on which the first participant was enrolled.

Intrauterine growth restriction (IUGR) remains one of the leading causes of perinatal morbidity and mortality. Although placental insufficiency is considered the major underlying mechanism, the molecular pathways responsible for impaired fetal growth are not fully understood. Progesterone is essential for maintaining pregnancy and exerts its biological effects through both classical nuclear receptors and membrane progesterone receptors. Among these, progesterone receptor membrane component-1 (PGRMC1), progesterone receptor membrane component-2 (PGRMC2), and members of the progestin and adipoQ receptor (PAQR) family have recently attracted attention because of their roles in placental development, angiogenesis, immune regulation, and maintenance of placental integrity. The present study will prospectively recruit women diagnosed with IUGR and healthy pregnant women delivering at the same institution. Placental samples collected immediately after delivery will undergo molecular analysis using quantitative real-time PCR to determine receptor expression levels. Clinical and obstetric characteristics together with neonatal outcomes will be recorded prospectively. The findings may contribute to a better understanding of the molecular mechanisms underlying placental dysfunction in IUGR and may identify potential biomarkers associated with adverse pregnancy outcomes.

Principal SponsorSamsun University
Study ContactCanan SOYER ÇALIŞKAN, MD, Associate ProfessorMore contacts
Last updated: July 14, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

90 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Case-Control

These studies compare people who have a disease (cases) with those who don't (controls). The goal is to look back at previous exposures or risk factors to identify what might have contributed to the disease.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Female

Biological sex of participants that are eligible to enroll.

From 18 to 45 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsFetal DiseasesGrowth DisordersCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesPathologic ProcessesPregnancy ComplicationsPathological Conditions, Signs and SymptomsFetal Growth Retardation

Criteria

1 inclusion criteria required to participate
Singleton pregnancy Maternal age 18-45 years Diagnosis of IUGR according to institutional criteria

1 exclusion criteria prevent from participating
Multiple pregnancy Major fetal structural anomaly Chromosomal abnormality Congenital infection Maternal chronic systemic disease Autoimmune disease Chronic hypertension Pregestational diabetes mellitus Placental abruption Intrauterine fetal demise

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Samsun University Faculty of Medicine Samsun Training and Research Hospital

Samsun, Turkey (Türkiye)Open Samsun University Faculty of Medicine Samsun Training and Research Hospital in Google Maps
Recruiting
One Study Center